NeuroVive Pharmaceutical AB Interim report January – June 2017
Strategic in-licensing broadens the project portfolio
Press releases
NeuroVive Pharmaceutical AB Interim report January – March 2017
Broadened project portfolio
NeuroVive Pharmaceutical AB publishes 2016 Annual report
Lund, Sweden, March 23, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that the English version of the Annual report for ...
NeuroVive Pharmaceutical AB Year End Report January – December 2016
Important steps forward and new research collaborations
NeuroVive Pharmaceutical AB Interim Report January – September 2016
New business model generates opportunities
NeuroVive Pharmaceutical – Interim report January-June 2016
Business operations
NeuroVive: Interim Report 1 Jan. 2016 to 31 Mar. 2016
Full speed ahead First Quarter (1 Jan. 2016 – 31 Mar. 2016)Net revenues were SEK 0 (0) and other operating income was SEK 46,000 (49,000).Loss before tax was SEK 10,916,000 […]
NeuroVive Pharmaceutical publishes 2015 annual report
NeuroVive Pharmaceutical AB (publ) today announced that the English version of the annual report for 2015 is now available on the company's website www.neurovive.com. The annual report can also be acc ...
NeuroVive: Year-End Report 1 Jan. 2015 – 31 Dec. 2015
Fourth Quarter (1 Oct. 2015 - 31 Dec. 2015) · Net revenues were SEK 0 (0) and other operating income was SEK 23,000 (8,000). · Loss before tax was SEK -7,366,000 (-17,346,000). · Earnings per share* w ...
NeuroVive: Interim Report 1 Jan. 2015 to 30 Sep. 2015
Focus forward on R&D
NeuroVive: Interim Report 1 Jan. 2015 to 31 Jun. 2015
Negative top-line result of phase III study and continued progress in other clinical projects
NeuroVive: Interim report 1 Jan. 2015 till 31 Mar. 2015
Capital raising characterizes NeuroVive ́s first quarter